3SOF

Quote from: AussieTrader on October 12, 2006, 08:36:09 AM
Hey Setravis, I thought you'd be mentionng our friend IGTG. Interesting to see where it goes from here, huge volume and price spike on the news, would suggest continuation is likely.
Good luck

Oh yes, Aussie !
You know I would be on this like "Stink on a Skunk"....

+42.11% ....Volume @ 463,853

Broke through the 200-day MA.......

Broke through and closed above the 200-day MA....
Another awesome day of volume and price action.
Day's Range: 0.12 - 0.18.........Closed @ 0.17   

52wk Range: 0.03 - 0.44

Volume: 2,484,943
Avg Vol (3m): 100,250

I think it's ready to take another shot at
moving north.....JMHO.....of course.

52wk Range: 0.03 - 0.44

Volume: 916,524
Avg Vol (3m): 155,500

Some news out...



Press Release Source: Ingen Technologies, Inc.


Ingen Builds A Strong Foundation
Tuesday June 5, 8:15 am ET 
Major Achievements Accomplished


YUCAIPA, Calif., June 5 /PRNewswire-FirstCall/ -- Ingen Technologies, Inc. (OTC: IGTG - News), a medical device manufacturer, announced today that the new OxyView® product has been registered and classified by the Food and Drug Administration. In addition, the company has completed the required SEC filings to be fully compliant with its periodic reporting obligations.
ADVERTISEMENT



The Company's flagship product, OxyView®, is now an FDA registered and classified device. OxyView® is a proprietary in-line pneumatic flow-meter that provides visual monitoring of oxygen flow-rate for patients in the hospital, surgical room, home oxygen therapy, nursing homes and emergency response facilities as well as provides a use with commercial aviation product manufacturers of oxygen delivery systems. OxyView® is a cutting edge product compared to the type of flow meters currently in the market that are dependent on gravity for operation and can only be attached to the regulator or source. OxyView® is gravity-independent and can function in any position; it can be attached in-line and within inches of the patient regardless of any source. OxyView® is much less expensive, more assessable and more accurate than the flow meters currently in the market. More important, OxyView® enhances the safety, assurance and accuracy of oxygen flow for patients being administered oxygen from any source, and unlike all of the other flow meters, OxyView® quickly and easily attaches to any cannula close to the patient. OxyView® can quickly provide information to the patient regarding proper flow rate or any obstruction between the patient and the source. OxyView® can prevent substantial Medicare costs for maintenance and repair of respiratory equipment.

"Ingen has sold thousands of OxyView® units since its' introduction last November. Sales have recently increased this 4th quarter (Ingen's fiscal year is May 31 to June 1). We have 12 new distributors in the USA and abroad, and are finalizing negotiations with one of the world's largest distributor of respiratory products. This distributor has requested sole distribution of OxyView®. We expect to close negotiations this month," said Scott Sand, CEO & Chairman of Ingen Technologies.

There are millions of people each year that require home oxygen therapy, and there are many more who require oxygen during hospitalizations and medical emergencies. This market continues to expand with the growing elderly population. OxyView® is sold in the USA, Canada, European Communities, Japan and the People's Republic of China. The company has issued and pending patents in the US, Canada, European Communities, Japan and People's Republic of China.

The Company's Salt Lake City based auditing firm, Child-Van Wagoner- Bradshaw, has completed the remaining audits/reviews for the period from 1999- 2004 and all of the required K-SB and Q-SB documents were filed with the SEC through EDGAR in May-2007. Ingen Technologies, Inc., a Georgia Corporation, was formed as a result of a reverse merger in March 2004 whereby Ingen became a publicly-owned company and commenced trading in the Over-The-Counter market on the Pink Sheets. Ingen (GA) is a holding company which owns intellectual property rights to certain proprietary devices which primarily provide diagnostic and safety features to health practitioners and patients. Operations are conducted through a 100%-owned subsidiary, Ingen Technologies, Inc. of Nevada, which has been in business since 1999 when Chairman/CEO Scott R. Sand founded it. The principal executive office is in Yucaipa, CA, northeast of Los Angeles.

"Although we immediately commenced with our reporting obligations at the time of the 2004 merger, there were no filings done by the previous management of the public company between 1999-2004. This has been our 'Achilles Heal' in being able to move to the OTCBB and file any type of registration to continue funding various new projects. Today Ingen is now current with all of its reporting obligations, and both the OTCBB and filing of future registrations are within close reach," said Thomas Neavitt, CFO of Ingen Technologies.

Scott Sand, CEO further stated: "This is a monumental accomplishment for this company and for our shareholders. We have forged our way through, moving forward steadily and against difficulties, and accomplished building the necessary foundation upon which I believe we can grow a successful and fruitful company with increased earnings and shareholder value. The time has come for Ingen to succeed."

About Ingen Technologies, Inc.

Ingen has devised a business model with some very appealing operational and economic aspects. First, its core strength is obtaining intellectual property rights (owning patents and trademarks) to technologically advanced products, particularly with medical applications for the elderly portion of the population. There, aging increases the incidence of balance and breathing disorders. Second, Ingen out-sources its manufacturing, deliberately avoiding the necessary investment in, and headaches of, manufacturing. Third, in the case of Secure Balance®, OxyView® and OxyAlert®, the sales function is, and will be, outsourced to organizations with existing marketing channels (and Rolodexes). Again, Ingen escapes something many companies do not -- the costly and time-consuming necessity to create an internal sales force. There is a rational quid pro quo: Ingen gains immediate access to a productive marketing organization; the latter gains equally rapid access to an additional, and attractive, product to pour through its distribution pipeline. Thus, there are mutual -- and major -- economic efficiencies and timesaving, for both parties.

There is a real economic savvy to Ingen's approach in two particular respects. First, overhead expenses are sliced to a minimum: no internal manufacturing or selling. Therefore, a big chunk of any future incremental revenue growth would flow through the income statement to earnings. Second, in the future, Ingen is positioned to add other interesting technologies to its product portfolio, thereby boosting potential revenues and leveraging earnings.


    For more information, visit:  www.ingen-tech.com

    Contact:  Scott R. Sand, C.E.O & Chairman
              Ingen Technologies, Inc. - Administrative Office
              35193 Avenue "A", Suite-C
              Yucaipa, California 92399
              Phone: (800) 259-9622 or (909) 790-7180
              Fax: (800) 777-1186 or (909) 795-6340
              Email: [email protected]

              A Member of the Better Business Bureau
              A Member of the Chamber of Commerce
              A Licensed Business in the City of Yucaipa

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

--------------------------------------------------------------------------------
Source: Ingen Technologies, Inc.

An old friend...

There's a Double Bottom on the 1 year chart.
Take look at the MACD 13-day MA, at point of crossing the 50-day MA.
Closed above the 200-day MA.

+34.92%.....Volume @ 152,266

If only I could see some more buying interest in the form of volume !
Maybe soon, the chart is looking better...

52wk Range: 0.02 - 0.19
Volume: 290,150
Avg Vol (3m): 58,148.9

Changed Ticker Symbol
IGTG.PK is no longer valid. It has changed to IGNT.PK


updated chart look...

Press Release Source: Ingen Technologies, Inc.
Ingen Files Quarterly Financials and Moves Forward With Great Promise
On Friday May 15, 2009, 6:45 am EDT


YUCAIPA, Calif., May 15, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Other OTC:IGNT.PK - News) a leading Global Medical Device manufacturer focused in the $ 4 Billion U.S. Respiratory Market for the growing ageing and emerging markets for Home (DME), Hospital and Aviation Industries announced today that they have complied with the reporting obligations of FINRA and the PINK OTC Markets.

The company was recently notified by PINK OTC Markets that after a review of the information posted to pinksheets.com, they have determined that the company has met the requirements for the Current Information tier for the period ending 02/28/2009.

Ingen Technologies has seen a slight increase in their Oxyview sales and distribution interest during the past two quarters, including several major events occurring with various OEM partnership negotiations that will be announced in the near future. ``We are discussing OEM partnerships with two large global distributors that have a strong foot-hold in the pharmaceutical and respiratory home medical equipment arena,'' stated Thomas Neavitt, Chief Financial Officer of Ingen.

The company has recently received issuance from China for the Oxyview patent and intellectual property rights in that country. With patents pending in the entire European Community and Japan, the company foresees no problems preventing their issuance as scheduled later this year.

About Oxyview:

Oxyview is a proprietary medical device with US issued patents that stands alone in an increasing patient home oxygen therapy market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, according to the World Health Organization, and another 12 million patients that are undiagnosed in the US. COPD is the fifth leading cause of death in the US and there are 600 million COPD patients worldwide where in most cases, COPD is either the first or second leading cause of death in other countries. The majority of COPD patients require continued home oxygen therapy, which includes all of the required equipment supplied by the home (DME) provider. With the new regulations for oxygen reimbursement in the US, the home (DME) providers need to cut costs to stay in business. Oxyview provides a substantial savings as a result of decreasing the number of service calls for the home (DME) provider. Oxyview is a pneumatic metering device that displays oxygen flow near the patient. The Oxyview flow meter easily and quickly installs on to the oxygen tubing nearest the patient where oxygen flow matters the most. Without the Oxyview, patients cannot confirm oxygen flow, and as a result there is an increase in anxiety and the patient calls the home (DME) provider with concerns. Oxyview also allows the home (DME) provider to trouble-shoot other equipment problems over the telephone which eliminates an on-site visit with the patient. More important, the Oxyview provides the patient with more assurance that they are receiving adequate and prescribed oxygen flow. The Oxyview costs less than a single service call.

http://www.ingen-tech.com

The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

Contact:
          Ingen Technologies, Inc.
          Chris Wirth
          909-790-7180
          [email protected]
          www.ingen-tech.com

Press Release Source: Ingen Technologies, Inc.
Oxyview Purchase Orders Increase 200% While Moving Toward the $30M Sales Potential in the $4 Billion Respiratory Market
On Thursday April 23, 2009, 6:45 am EDT


YUCAIPA, Calif., April 23, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Other OTC:IGNT.PK - News), a leading Global Medical Device manufacturer focused in the $4 Billion Respiratory Market for the growing ageing and emerging markets for Home (DME), Hospital and Aviation Industries announced today that orders from existing OEM partners, and new home oxygen DME providers have increased by over 200% just in the past 30 days.

The company received a second bulk purchase order from Qosina Corporation on April 3rd of this month, and then recently a third bulk purchase order for triple the quantity of Oxyview's on April 16th of this month. Qosina, founded in 1980, is a leading global components supplier to the medical and pharmaceutical industries. In addition, there has been an increase in Oxyview sales over the past 30 days from new DME providers and online patient purchasing, including Summit Home Medical, and CHAMPS Medical. Other companies like Airlift Unlimited and American HomePatient have expressed an interest and are evaluating the Oxyview. American HomePatient provides oxygen equipment and supplies, patient assessment and follow up, and sleep therapy equipment (CPAP and supplies) to patients in 13 mid-west states in the U.S.A.

Over the next two decades, medical costs related to chronic obstructive pulmonary disease (COPD) will total approximately $832.9 billion in the United States, according to a study to be presented at the American Thoracic Society International Conference on May 22nd. The potential market for Oxyview would result in $30M annually in the US alone. The estimated future costs related to COPD, found that the disease will cost $176.6 billion in the U.S. over the next five years, and $389.2 billion over the next 10 years.

``While the home durable medical equipment (DME) providers benefit through the use of the Oxyview flow meter with their patients and clinical network, Oxyview sales are expected to increase as the respiratory industry continues to recognize the cost savings experienced through the use of our new Oxyview product. Ingen owns the intellectual properties and manufactures Oxyview, allowing us to offer the device at a competitive price, making it very affordable for the patient, and providing our distribution and the company with better than average margins and profits. Overall, the Oxyview continues to save government healthcare costs providing a more efficient means for home oxygen therapy, and improving quality care for the home oxygen patient,'' stated Thomas Neavit, CFO of Ingen Technologies.

About Oxyview:

Oxyview stands alone in an increasing patient market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, according to the World Health Organization, and another 12 million patients that are undiagnosed in the U.S. COPD is the fifth leading cause of death in the U.S. and there are 600 million COPD patients worldwide where in most cases, COPD is either the first or second leading cause of death in other countries. The majority of COPD patients require continued home oxygen therapy, which includes all of the required equipment supplied by the home (DME) provider. With the new regulations for oxygen reimbursement in the U.S., the home (DME) providers need to cut costs to stay in business. Oxyview provides a substantial savings as a result of decreasing the number of service calls for the home (DME) provider. Oxyview is a pneumatic metering device that displays oxygen flow near the patient. The Oxyview flow meter easily and quickly installs on to the oxygen tubing nearest the patient where oxygen flow matters the most. Without the Oxyview, patients cannot confirm oxygen flow, and as a result there is an increase in anxiety and the patient calls the home (DME) provider with concerns. Oxyview also allows the home (DME) provider to trouble-shoot other equipment problems over the telephone which eliminates an on-site visit with the patient. More important, the Oxyview provides the patient with more assurance that they are receiving adequate and prescribed oxygen flow. The Oxyview cost less than a single service call.

The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472

http://www.ingen-tech.com

http://www.qosina.com

http://www.ahom.com/cgi-bin/search.pl/ShowBillingCenters

http://www.thoracic.org/sections/publications/press-releases/conference/articles/2006/press-releases/copd-will-cost-us-800-billion-over-next-20-years-study-predicts.html

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

Contact:
          Ingen Technologies, Inc.
          Chris Wirth
          909-790-7180
          [email protected]
          www.ingen-tech.com

Press Release Source: Ingen Technologies, Inc.
Ingen is Granted Patent Rights for China in Estimated $200M Market
On Thursday April 16, 2009, 3:48 pm EDT


YUCAIPA, Calif., April 16, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Other OTC:IGNT.PK - News), a leading global Medical Device Manufacturer focused on the $4B Respiratory market with their Oxyview products for the growing aging population and emerging markets for Home (DME), Hospital and Aviation industries announced today that the Chinese State Intellectual Property for the People's Republic of China is prepared to grant patent rights for Oxyview.

On April 10, 2009 the company was notified by the Del Mar, California based American Patent & Trademark Law Center that the Chinese patent application no. 200710005067.4 / Docket no. 3659-CHI will be granted for the Peoples Republic of China. In China, chronic obstructive pulmonary disease (COPD) in people over the age of 40 is much more prevalent than previously thought, according to researchers in Guangdong. According to an estimation by the World Health Organization, COPD ranks first among the burdens of diseases in China and accounts for one million deaths and five million disabilities each year.

Oxyview offers cost savings for the entire global oxygen industry. ``It has been 90 days since the 36-month cap on oxygen equipment rental went into effect in the USA. Most providers have found a way to stay in business; although the industry is only faced with the initial challenge associated with revenue reduction and lower reimbursement. Oxyview will play a small role in a huge and growing industry by eliminating unnecessary service calls to the home oxygen patient, and easily diagnosing equipment malfunction that could lead to malpractice suits. Oxyview stands alone in the in-line gravity independent flow-meter market, with potential sales of $30M annually, and savings in the industry of 10 times that amount. One Oxyview costs less than a single service call,'' Stated Scott Sand, CEO and Chairman of Ingen Technologies.

http://www.sciencedaily.com/releases/2007/10/071012080126.htm

The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.

Contact:
          Ingen Technologies, Inc.
          Chris Wirth
          909-790-7180
          www.info@ingen-tech.com

Ignt a strong buy today. News came out this morning. Keep this stock on your radar list. I am currently going to take a position with a few other investors on this company. A good time to buy this stock while the price is low. I expect this stock to break through the 20 day ma of .0021 and bounce hold at the 50 day ma of .0026. good luck to you all!!

IGNT a leading manufacturer of respiratory medical devices, recently announced that it has received several bulk purchases from various hospitals around the country. Columbia Memorial Hospital submitted a bulk purchase order for the new Oxyview Pulse Oximeter, and this is a strong indication of increased sales for 2010. Yesterday close +5.56% Watch for a run today!! IMO

Ignt had news today.Stock is trading well today. Myself and other smart money have taken a position in this stock today. We should see more price aprecation today and this week. The new magazine insert should bring more focus towards the company and the great products they produce. This company has a bright future and we can all profit from it. Remember this is my opinion and to do your own dd. Hope all your stocks are in the green!!!